Antibody Drug Conjugate (ADC) Analysis
A novel method for drug antibody ratio determinations based on SEC-MALS in conjunction with UV absorption and differential refractive index detection.
A novel method for drug antibody ratio determinations based on SEC-MALS in conjunction with UV absorption and differential refractive index detection.
There has been a significant resurgence in the development of antibody-drug conjugates (ADC) as target-directed therapeutic agents for cancer treatment. Among the factors critical to effective ADC design is the drug antibody ratio (DAR). The DAR describes the degree of drug addition which directly impacts both potency and potential toxicity of the therapeutic, and can have significant effects on properties such as stability and aggregation. Determination of DAR is, therefore, of critical importance in the development of novel ADC therapeutics.
DAR is typically assessed by mass spectrometry (MALDI-TOF or ESI-MS) or UV spectroscopy. Calculations based on UV absorption are often complicated by similarities in extinction coefficients of the antibody and small molecule. Mass spectrometry, though a powerful tool for Mw determination, depends on uniform ionization and recovery between compounds — which is not always the case for ADCs.
We present here a method for DAR determination based on SEC-MALS in conjunction with UV absorption and differential refractive index detection. Figure 1 shows UV traces for two model ADCs; molecular weights of the entire ADC complexes are determined directly from light scattering data.
Figure 1: Molar masses for two distinct ADC formulations are determined using SEC-MALS analysis.
Component analysis is automated within the ASTRA 6 software package by using the differential refractive index increments (dn/dc) and extinction coefficients, which are empirically determined for each specie or mined from the literature, to calculate the molar mass of the entire complex as well as for each component of the complex.
Figure 2: Molar masses for the antibody and total appended drug are calculated in the ASTRA software package based on prior knowledge of each component’s extinction coefficent and dn/dc, allowing determination of DAR based on a nominal Mw of 1250 Da for an individual drug.
In this example an antibody has been alkylated with a compound having a nominal molecular weight of 1250 Da (Figure 2). Molar masses of the antibody fractions are similar, which indicates that the overall differences between the two formulations reflect distinct average DARs which are consistent with values obtained by orthogonal techniques. Note that the molar mass traces for the conjugated moiety represent the total amount of attached pendant groups; the horizontal trends indicate that modification is uniform throughout the population eluting in that peak.
Wyatt Technology
6300 Hollister Avenue, Santa Barbara, CA 93117
tel. +1 (805) 681-9009, fax +1 (805) 681-0123
Website: www.wyatt.com
SEC-MALS of Antibody Therapeutics—A Robust Method for In-Depth Sample Characterization
June 1st 2022Monoclonal antibodies (mAbs) are effective therapeutics for cancers, auto-immune diseases, viral infections, and other diseases. Recent developments in antibody therapeutics aim to add more specific binding regions (bi- and multi-specificity) to increase their effectiveness and/or to downsize the molecule to the specific binding regions (for example, scFv or Fab fragment) to achieve better penetration of the tissue. As the molecule gets more complex, the possible high and low molecular weight (H/LMW) impurities become more complex, too. In order to accurately analyze the various species, more advanced detection than ultraviolet (UV) is required to characterize a mAb sample.
